Literature DB >> 27310245

What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada?

Richard Williams1, Ashok Malla2,3, Marc-Andre Roy4,5, Ridha Joober2,3, Rahul Manchanda6,7, Phil Tibbo8,9, Nicola Banks10, Ofer Agid11,12.   

Abstract

Research and development of early intervention (EI) services for first-episode psychosis have brought much-needed transformation of service delivery for this serious mental disorder to many jurisdictions. The effectiveness of the EI model of service delivery is contingent on timely access to all evidence-informed treatment interventions, including a rational approach to pharmacotherapy. In this perspective paper, we present a brief review of the well-established effectiveness of clozapine in patients who clearly show lack of response to regular antipsychotic therapy. We concentrate, in particular, on the need to identify eligibility for clozapine therapy very early on following failure of treatment on 2 antipsychotic medications. We suggest that attention to the low use of clozapine in the very early phase of treatment of psychosis may be of particular value, as the response to clozapine at this stage is likely to produce larger benefits in other domains of outcomes because of the greater retention of patients' personal and social agency.

Entities:  

Keywords:  clozapine; first episode; treatment resistance psychosis

Mesh:

Substances:

Year:  2016        PMID: 27310245      PMCID: PMC5298522          DOI: 10.1177/0706743716651049

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  49 in total

Review 1.  Treating psychosis: is there more to early intervention than intervening early?

Authors:  A M Malla; R M Norman
Journal:  Can J Psychiatry       Date:  2001-09       Impact factor: 4.356

2.  The personal meaning of recovery among individuals treated for a first episode of psychosis.

Authors:  Deborah Windell; Ross Norman; Ashok K Malla
Journal:  Psychiatr Serv       Date:  2012-06       Impact factor: 3.084

3.  Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study.

Authors:  Ashok Malla; Ross Norman; Norbert Schmitz; Rahul Manchanda; Laura Béchard-Evans; Jatinder Takhar; Raj Haricharan
Journal:  Psychol Med       Date:  2006-03-06       Impact factor: 7.723

4.  Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years.

Authors:  Clifford M Cassidy; Ross Norman; Rahul Manchanda; Norbert Schmitz; Ashok Malla
Journal:  Schizophr Bull       Date:  2009-03-25       Impact factor: 9.306

Review 5.  The dissemination and implementation of evidence-based psychological treatments. A review of current efforts.

Authors:  R Kathryn McHugh; David H Barlow
Journal:  Am Psychol       Date:  2010 Feb-Mar

6.  Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.

Authors:  K Atkin; F Kendall; D Gould; H Freeman; J Liberman; D O'Sullivan
Journal:  Br J Psychiatry       Date:  1996-10       Impact factor: 9.319

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 8.  Suicide in schizophrenia: risk factors and clozapine treatment.

Authors:  H Y Meltzer
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

9.  Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.

Authors:  Amanda J Wheeler
Journal:  Ann Pharmacother       Date:  2008-05-13       Impact factor: 3.154

10.  Early use of clozapine for poorly responding first-episode psychosis.

Authors:  Ofer Agid; Gary Remington; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Journal:  J Clin Psychopharmacol       Date:  2007-08       Impact factor: 3.153

View more
  5 in total

1. 

Authors:  Japheth Bool; Alex Crawley; Annabelle Wanson; Breanna Davis; Katelyn Halpape
Journal:  Can Fam Physician       Date:  2021-05       Impact factor: 3.275

2.  Pharmacotherapy management of schizophrenia for family physicians.

Authors:  Japheth Bool; Alex Crawley; Annabelle Wanson; Breanna Davis; Katelyn Halpape
Journal:  Can Fam Physician       Date:  2021-05       Impact factor: 3.275

3.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

Review 4.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

Review 5.  Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.

Authors:  Candice E Crocker; Philip G Tibbo
Journal:  Front Pharmacol       Date:  2018-10-18       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.